AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7963779 — intervention group
Group type: EXPERIMENTAL
Intervention: Meperidine 50 mg i.v.
Number of subjects: 60
Study 7963779 — intervention group
Group type: COMPARATOR
Intervention: Saline solution
Number of subjects: 60
Study 3308829 — intervention group
Group type: EXPERIMENTAL
Intervention: fenfluramine
Number of subjects: 20
Study 3308829 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 20
Study 31501493 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan with sodium chloride (NaCl) supplementation (100 mmol/24 h)
Number of subjects: 28
Study 31501493 — intervention group
Group type: COMPARATOR
Intervention: Telmisartan with placebo capsules
Number of subjects: 28
Study 30415175 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine (OLZ) users
Number of subjects: 128
Study 30415175 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (HC)
Number of subjects: 128
Study 27515875 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi
Number of subjects: 374
Study 27515875 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking
Number of subjects: 374
Study 27515875 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 374
Study 24183325 — intervention group
Group type: EXPERIMENTAL
Intervention: Gap balancing
Number of subjects: 103
Study 24183325 — intervention group
Group type: COMPARATOR
Intervention: Measured resection
Number of subjects: 103
Study 22489515 — intervention group
Group type: EXPERIMENTAL
Intervention: Blade needle closed loosing and reduction with traction
Number of subjects: 65
Study 22489515 — intervention group
Group type: COMPARATOR
Intervention: Traditional traction
Number of subjects: 65
Study 20096611 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular aneurysm repair (EVAR)
Number of subjects: 404
Study 20096611 — intervention group
Group type: COMPARATOR
Intervention: No surgical intervention (control)
Number of subjects: 404
Study 18285411 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone (30 mg/d) for 16 weeks
Number of subjects: 30
Study 18285411 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 15738497 — intervention group
Group type: EXPERIMENTAL
Intervention: Various interventions (over 700 evaluated)
Number of subjects: 28669
Study 11944023 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant supplementation (400 IU of vitamin E, 500 mg of vitamin C, and 12 mg of beta-carotene daily)
Number of subjects: 18
Study 11944023 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant supplementation (800 IU of vitamin E, 1000 mg of vitamin C, and 24 mg of beta-carotene daily)
Number of subjects: 18
Study 11944023 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 9743957 — intervention group
Group type: EXPERIMENTAL
Intervention: HIT'88/'89 regimen (preradiation chemotherapy)
Number of subjects: 147
Study 9743957 — intervention group
Group type: COMPARATOR
Intervention: Standard regimen (CCNU, cisplatin, and vincristine after radiation therapy)
Number of subjects: 147
Study 8983939 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampicine Generic 300 mg capsules
Number of subjects: 12
Study 8983939 — intervention group
Group type: COMPARATOR
Intervention: Rimactan 300 mg capsules
Number of subjects: 12
Study 2517005 — intervention group
Group type: EXPERIMENTAL
Intervention: Rilmenidine (1 mg once or twice daily)
Number of subjects: 459
Study 2517005 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 459
Study 2517005 — intervention group
Group type: COMPARATOR
Intervention: Clonidine (0.150 mg once or twice daily)
Number of subjects: 459
Study 2517005 — intervention group
Group type: EXPERIMENTAL
Intervention: Rilmenidine (single dose)
Number of subjects: 459
Study 782477 — intervention group
Group type: EXPERIMENTAL
Intervention: CN 3123 (sulfamoxole/trimethoprim)
Number of subjects: 0
Study 782477 — intervention group
Group type: COMPARATOR
Intervention: Reference preparation
Number of subjects: 0
Study 7325577 — intervention group
Group type: COMPARATOR
Intervention: 26-gauge needle
Number of subjects: 797
Study 7325577 — intervention group
Group type: COMPARATOR
Intervention: 100 mg indomethacin administered six hours after blockade
Number of subjects: 797
Study 7325577 — intervention group
Group type: COMPARATOR
Intervention: 3000 ml fluid infusion during operation
Number of subjects: 797
Study 7325577 — intervention group
Group type: COMPARATOR
Intervention: Recumbency for 24 hours
Number of subjects: 797
Study 7325577 — intervention group
Group type: COMPARATOR
Intervention: Prophylactic epidural blood patching
Number of subjects: 797
Study 30839454 — intervention group
Group type: EXPERIMENTAL
Intervention: Communication intervention delivered by nurse interveners
Number of subjects: 12
Study 27720812 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise plus trigger point dry needling (TrP‐DN)
Number of subjects: 50
Study 27720812 — intervention group
Group type: COMPARATOR
Intervention: Exercise alone
Number of subjects: 50
Study 27785656 — intervention group
Group type: EXPERIMENTAL
Intervention: PATHS Curriculum
Number of subjects: 0
Study 27785656 — intervention group
Group type: COMPARATOR
Intervention: Attentional control
Number of subjects: 0
Study 25056584 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy with 300 index of reactivity mixture of Dermatophagoides pteronyssinus and Dermatophagoides farinae extracts for 12 months
Number of subjects: 484
Study 25056584 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 484
Study 22135048 — intervention group
Group type: EXPERIMENTAL
Intervention: Freeze-dried strawberry powder at 60 g/d
Number of subjects: 75
Study 22135048 — intervention group
Group type: EXPERIMENTAL
Intervention: Freeze-dried strawberry powder at 30 g/d
Number of subjects: 75
Study 19462699 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive impairment (CI) assessment using MMSE
Number of subjects: 745
Study 19462699 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate cognitive impairment (CI)
Number of subjects: 745
Study 19462699 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild cognitive impairment (CI)
Number of subjects: 745
Study 17224647 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib + Surgery
Number of subjects: 59
Study 17224647 — intervention group
Group type: COMPARATOR
Intervention: Surgery
Number of subjects: 59
Study 17224647 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 59
Study 15199361 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen (20 mg/d)
Number of subjects: 27
Study 15199361 — intervention group
Group type: COMPARATOR
Intervention: Control (healthy postmenopausal women)
Number of subjects: 27
Study 12530261 — intervention group
Group type: EXPERIMENTAL
Intervention: CHOP-Dexa-BEAM plus autologous hemopoietic cell transplantation
Number of subjects: 70
Study 12530261 — intervention group
Group type: COMPARATOR
Intervention: CHOP-Dexa-BEAM
Number of subjects: 70
Study 12530261 — intervention group
Group type: COMPARATOR
Intervention: CHOP
Number of subjects: 70
Study 9661605 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid (Liposyn II; 1.5 mL/min) and heparin (0.4 U/kg.min; L/H) infusion
Number of subjects: 7
Study 9661605 — intervention group
Group type: COMPARATOR
Intervention: Saline/glycerol (2.25 g/h; S/G) infusion
Number of subjects: 7
Study 7659838 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (group 2)
Number of subjects: 20
Study 7659838 — intervention group
Group type: COMPARATOR
Intervention: Control (group 1)
Number of subjects: 20
Study 2745669 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine administration during days 2-12 of ovarian hyperstimulation
Number of subjects: 0
Study 2745669 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 180193 — intervention group
Group type: EXPERIMENTAL
Intervention: SKF 40491
Number of subjects: 0
Study 180193 — intervention group
Group type: EXPERIMENTAL
Intervention: GLR9‐338
Number of subjects: 0
Study 180193 — intervention group
Group type: EXPERIMENTAL
Intervention: RP L9326
Number of subjects: 0
Study 180193 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31633607 — intervention group
Group type: EXPERIMENTAL
Intervention: Levobupivacaine 0.4 mg/kg with volume adjusted to 0.2 mL/kg of 0.2% or 0.4 mL/kg of 0.1%
Number of subjects: 40
Study 31633607 — intervention group
Group type: EXPERIMENTAL
Intervention: Levobupivacaine 0.4 mg/kg
Number of subjects: 40
Study 31633607 — intervention group
Group type: EXPERIMENTAL
Intervention: Levobupivacaine dosing regimen
Number of subjects: 40
Study 30652510 — intervention group
Group type: EXPERIMENTAL
Intervention: Crizotinib
Number of subjects: 0
Study 30652510 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 0
Study 27415645 — intervention group
Group type: EXPERIMENTAL
Intervention: PRB exercises combined with motivational group discussions twice weekly for 3 months
Number of subjects: 67
Study 27415645 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 67
Study 26721137 — intervention group
Group type: EXPERIMENTAL
Intervention: Pricking blood combined with moxibustion
Number of subjects: 40
Study 26721137 — intervention group
Group type: COMPARATOR
Intervention: Western medication (0.3 g ibuprofen orally twice a day for 10 days)
Number of subjects: 40
Study 23320605 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium at 0.15 mg kg(‐1)
Number of subjects: 360
Study 23320605 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium at 0.30 mg kg(‐1)
Number of subjects: 360
Study 23320605 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium at 0.45 mg kg(‐1)
Number of subjects: 360
Study 23320605 — intervention group
Group type: COMPARATOR
Intervention: Control (0 mg kg(‐1) selenium)
Number of subjects: 360
Study 21792049 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus (SRL) conversion
Number of subjects: 830
Study 21792049 — intervention group
Group type: COMPARATOR
Intervention: CNI continuation
Number of subjects: 830
Study 21792049 — intervention group
Group type: EXPERIMENTAL
Intervention: All other malignancies
Number of subjects: 830
Study 19397687 — intervention group
Group type: EXPERIMENTAL
Intervention: Polymerized-Collagen (2 mL, 12 intra-articular injections over 6 months)
Number of subjects: 53
Study 19397687 — intervention group
Group type: COMPARATOR
Intervention: Placebo (2 mL, 12 intra-articular injections over 6 months)
Number of subjects: 53
Study 19397687 — intervention group
Group type: COMPARATOR
Intervention: Polymerized-Collagen and Placebo
Number of subjects: 53
Study 17415541 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior access technique
Number of subjects: 40
Study 17415541 — intervention group
Group type: COMPARATOR
Intervention: Posterior access technique
Number of subjects: 40
Study 15127149 — intervention group
Group type: EXPERIMENTAL
Intervention: Constitutionally weak voices
Number of subjects: 33
Study 15127149 — intervention group
Group type: COMPARATOR
Intervention: Normal vocal constitution
Number of subjects: 33
Study 12067865 — intervention group
Group type: EXPERIMENTAL
Intervention: ondansetron 4 mg iv just prior to induction of anesthesia
Number of subjects: 150
Study 12067865 — intervention group
Group type: EXPERIMENTAL
Intervention: acupressure wristbands applied at the P6 points
Number of subjects: 150
Study 12067865 — intervention group
Group type: COMPARATOR
Intervention: Control group (no active intervention)
Number of subjects: 150
Study 9619942 — intervention group
Group type: EXPERIMENTAL
Intervention: Unreamed titanium nails
Number of subjects: 48
Study 9619942 — intervention group
Group type: COMPARATOR
Intervention: Reamed nails
Number of subjects: 48
Study 7653449 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 6595
Study 7653449 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6595
Study 2565682 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta blockers
Number of subjects: 12
Study 2565682 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 70931 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc sulphate, 0.6 g daily for 12 weeks (some patients treated for 4 or 8 weeks)
Number of subjects: 39
Study 70931 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablets
Number of subjects: 39
Study 70931 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc sulphate
Number of subjects: 39
Study 70931 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 31878319 — intervention group
Group type: EXPERIMENTAL
Intervention: Exergame intervention (24 weeks, 120 min/week, 2 sessions)
Number of subjects: 55
Study 31878319 — intervention group
Group type: EXPERIMENTAL
Intervention: Detraining (24 weeks after intervention)
Number of subjects: 55
Study 31878319 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 55
Study 28055119 — intervention group
Group type: EXPERIMENTAL
Intervention: Attention and Interpretation Modification for Fear of Breast Cancer Recurrence (AIM‐FBCR)
Number of subjects: 110
Study 28055119 — intervention group
Group type: COMPARATOR
Intervention: Control condition program
Number of subjects: 110
Study 30930573 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound phonophoresis therapy with Lofnac Gel (diclofenac and methyl salicylate)
Number of subjects: 70
Study 30930573 — intervention group
Group type: COMPARATOR
Intervention: Ultrasound with water as coupling medium
Number of subjects: 70
Study 30930573 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound phonophoresis therapy with Lofnac Gel
Number of subjects: 70
Study 24279128 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical mathematics bridge and tutoring programs
Number of subjects: 105
Study 24279128 — intervention group
Group type: COMPARATOR
Intervention: Previous years without intervention
Number of subjects: 105
Study 21136267 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-umbilical oxytocin 100 IU diluted in 30 ml of saline
Number of subjects: 61
Study 21136267 — intervention group
Group type: COMPARATOR
Intervention: Controlled cord traction only
Number of subjects: 61
Study 19075284 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat diet high in vegetables, fruit, and fiber
Number of subjects: 2967
Study 19075284 — intervention group
Group type: COMPARATOR
Intervention: Five-a-day dietary guidelines (Control)
Number of subjects: 2967
Study 17509436 — intervention group
Group type: EXPERIMENTAL
Intervention: Trendelenburg test
Number of subjects: 36
Study 17509436 — intervention group
Group type: EXPERIMENTAL
Intervention: Active Straight Leg Raise (ASLR) test
Number of subjects: 36
Study 17509436 — intervention group
Group type: EXPERIMENTAL
Intervention: Breathing pattern during ASLR
Number of subjects: 36
Study 17509436 — intervention group
Group type: EXPERIMENTAL
Intervention: Trendelenburg test and ASLR tests
Number of subjects: 36
Study 17509436 — intervention group
Group type: EXPERIMENTAL
Intervention: Trendelenburg test, ASLR test, and breathing pattern assessment
Number of subjects: 36
Study 15492460 — intervention group
Group type: EXPERIMENTAL
Intervention: Tussah silk-processing workers
Number of subjects: 197
Study 15492460 — intervention group
Group type: COMPARATOR
Intervention: Control workers
Number of subjects: 197
Study 11676979 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV-16 DNA detection in cervical carcinoma
Number of subjects: 50
Study 11676979 — intervention group
Group type: EXPERIMENTAL
Intervention: Spontaneous apoptosis analysis in cervical carcinoma
Number of subjects: 50
Study 11676979 — intervention group
Group type: EXPERIMENTAL
Intervention: TNF-alpha quantification in cervical carcinoma
Number of subjects: 50
Study 11676979 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of TNF-alpha with apoptosis
Number of subjects: 50
Study 11676979 — intervention group
Group type: EXPERIMENTAL
Intervention: Cut-off value for TNF-alpha
Number of subjects: 50
Study 9338642 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsatile flow at pump flow rates of 0.6, 1.2, and 2.4 L x m2 x min(‐1)
Number of subjects: 40
Study 9338642 — intervention group
Group type: COMPARATOR
Intervention: Nonpulsatile flow at pump flow rates of 0.6, 1.2, and 2.4 L x m2 x min(‐1)
Number of subjects: 40
Study 8433024 — intervention group
Group type: EXPERIMENTAL
Intervention: Endocavitary hyperthermia combined with 10 MeV X-ray or 60CO (group A)
Number of subjects: 122
Study 8433024 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative radiation (group B)
Number of subjects: 122
Study 8433024 — intervention group
Group type: COMPARATOR
Intervention: Surgery (group C)
Number of subjects: 122
Study 8433024 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 Gy plus heat
Number of subjects: 122
Study 8433024 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 Gy alone
Number of subjects: 122
Study 8433024 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 Gy plus heat
Number of subjects: 122
Study 8433024 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 Gy alone
Number of subjects: 122
Study 3318993 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg rimexolone
Number of subjects: 137
Study 3318993 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg rimexolone
Number of subjects: 137
Study 3318993 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg rimexolone
Number of subjects: 137
Study 3318993 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 137
Study 31596969 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of collaboration within the partnership
Number of subjects: 238
Study 31596969 — intervention group
Group type: EXPERIMENTAL
Intervention: Sense of community responsibility
Number of subjects: 238
Study 30025006 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous block
Number of subjects: 8
Study 30025006 — intervention group
Group type: COMPARATOR
Intervention: Xenogeneic block
Number of subjects: 8
Study 27601891 — intervention group
Group type: EXPERIMENTAL
Intervention: FreeO2
Number of subjects: 50
Study 27601891 — intervention group
Group type: COMPARATOR
Intervention: Manual oxygen titration
Number of subjects: 50
Study 25059747 — intervention group
Group type: EXPERIMENTAL
Intervention: Operative treatment (open reduction and internal fixation)
Number of subjects: 151
Study 25059747 — intervention group
Group type: COMPARATOR
Intervention: Non-operative treatment
Number of subjects: 151
Study 25059747 — intervention group
Group type: EXPERIMENTAL
Intervention: Operative treatment
Number of subjects: 151
Study 21898023 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic colectomy (group B)
Number of subjects: 40
Study 21898023 — intervention group
Group type: COMPARATOR
Intervention: Open colectomy (group A)
Number of subjects: 40
Study 21258131 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic screening
Number of subjects: 42376
Study 21258131 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 42376
Study 21258131 — intervention group
Group type: EXPERIMENTAL
Intervention: Both arms
Number of subjects: 42376
Study 18076224 — intervention group
Group type: EXPERIMENTAL
Intervention: Blocked multiple-set regimen
Number of subjects: 42
Study 18076224 — intervention group
Group type: COMPARATOR
Intervention: Single-set regimen
Number of subjects: 42
Study 16219013 — intervention group
Group type: EXPERIMENTAL
Intervention: Orlistat 120 mg three times daily plus a diet providing an energy deficit of 500 kcal/day
Number of subjects: 430
Study 16219013 — intervention group
Group type: EXPERIMENTAL
Intervention: Orlistat 120 mg three times daily plus a diet providing an energy deficit of 1000 kcal/day
Number of subjects: 430
Study 16219013 — intervention group
Group type: COMPARATOR
Intervention: Both diet treatment groups (500 kcal/day and 1000 kcal/day)
Number of subjects: 430
Study 12355350 — intervention group
Group type: EXPERIMENTAL
Intervention: Glossodynia patients
Number of subjects: 17
Study 10036559 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management educational program
Number of subjects: 29
Study 7552617 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative radiotherapy (IORT) with doses of 12.5-16.5 Gy
Number of subjects: 43
Study 7552617 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant external beam radiation (given to 23 of the 27 patients receiving IORT) with total doses ranging from 24 to 50 Gy
Number of subjects: 43
Study 1527129 — intervention group
Group type: EXPERIMENTAL
Intervention: prefabricated functional brace
Number of subjects: 39
Study 1527129 — intervention group
Group type: COMPARATOR
Intervention: long-arm cast
Number of subjects: 39
Study 2410720 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril 20 mg
Number of subjects: 13
Study 2410720 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril 40 mg
Number of subjects: 13
Study 2410720 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril 5 mg
Number of subjects: 13
Study 2410720 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril 10 mg
Number of subjects: 13
Study 2410720 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril 20 mg (hypertension group)
Number of subjects: 13
Study 2410720 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril 40 mg (hypertension group)
Number of subjects: 13
Study 2410720 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (congestive heart failure group)
Number of subjects: 13
Study 2410720 — intervention group
Group type: EXPERIMENTAL
Intervention: MK 422 (metabolite)
Number of subjects: 13
Study 31046527 — intervention group
Group type: EXPERIMENTAL
Intervention: Tele-education
Number of subjects: 0
Study 31046527 — intervention group
Group type: COMPARATOR
Intervention: Control group (delayed tele-education)
Number of subjects: 0
Study 29410329 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel sheath group
Number of subjects: 86
Study 29410329 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 86
Study 27581208 — intervention group
Group type: EXPERIMENTAL
Intervention: initial triple DMARD therapy (iTDT) with glucocorticoids (GCs) intramuscular
Number of subjects: 281
Study 27581208 — intervention group
Group type: EXPERIMENTAL
Intervention: initial triple DMARD therapy (iTDT) with an oral GC tapering scheme
Number of subjects: 281
Study 27581208 — intervention group
Group type: COMPARATOR
Intervention: initial MTX monotherapy (iMM) with GCs
Number of subjects: 281
Study 26717392 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intake (DI) group
Number of subjects: 30
Study 24027184 — intervention group
Group type: EXPERIMENTAL
Intervention: Total n-3 PUFAs (including ALA, EPA, DPA, DHA)
Number of subjects: 843